Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 226

1.

Non-thrombotic-, non-inhibitor-associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand's disease: a systematic review of prospective studies.

Franchini M, Makris M, Santagostino E, Coppola A, Mannucci PM.

Haemophilia. 2012 May;18(3):e164-72. doi: 10.1111/j.1365-2516.2011.02745.x. Epub 2012 Jan 18. Review.

PMID:
22250981
3.

Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies.

Coppola A, Franchini M, Makris M, Santagostino E, Di Minno G, Mannucci PM.

Haemophilia. 2012 May;18(3):e173-87. doi: 10.1111/j.1365-2516.2012.02758.x. Epub 2012 Feb 15. Review.

PMID:
22335611
5.

Progress in the treatment of bleeding disorders.

Bergman GE.

Thromb Res. 2011 Jan;127 Suppl 1:S3-5. doi: 10.1016/j.thromres.2010.10.007. Epub 2010 Oct 29. Review.

PMID:
21035836
6.

No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study.

Auerswald G, Bade A, Haubold K, Overberg D, Masurat S, Moorthi C.

Haemophilia. 2013 May;19(3):438-44. doi: 10.1111/hae.12075. Epub 2012 Dec 20.

PMID:
23279056
7.

Multiple congenital coagulopathies co-expressed with Von Willebrand's disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature.

Asatiani E, Kessler CM; Directors of the Comprehensive Hemophilia Treatment Centers in Region III.

Haemophilia. 2007 Nov;13(6):685-96. Review.

PMID:
17973844
8.

Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment.

Berntorp E, Astermark J, Baghaei F, Bergqvist D, Holmström M, Ljungberg B, Norlund A, Palmblad J, Petrini P, Stigendal L, Säwe J.

Haemophilia. 2012 Mar;18(2):158-65. doi: 10.1111/j.1365-2516.2011.02723.x. Epub 2011 Dec 12. Review.

PMID:
22151198
9.

The factor VIII/von Willebrand factor complex: basic and clinical issues.

Federici AB.

Haematologica. 2003 Jun;88(6):EREP02. Review.

PMID:
12826528
10.

The safety of pharmacologic options for the treatment of persons with hemophilia.

Franchini M, Mannucci PM.

Expert Opin Drug Saf. 2016 Oct;15(10):1391-400. doi: 10.1080/14740338.2016.1208747. Epub 2016 Jul 18. Review.

PMID:
27367551
12.

Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review.

Franchini M, Tagliaferri A, Mengoli C, Cruciani M.

Crit Rev Oncol Hematol. 2012 Jan;81(1):82-93. doi: 10.1016/j.critrevonc.2011.01.002. Epub 2011 Jan 31. Review.

PMID:
21277222
13.

Coagulation products and their uses.

Shord SS, Lindley CM.

Am J Health Syst Pharm. 2000 Aug 1;57(15):1403-17; quiz 1418-20. Review.

PMID:
10938981
14.

Pioneering designs for recombinant coagulation factors.

Schulte S.

Thromb Res. 2011;128 Suppl 1:S9-12. doi: 10.1016/S0049-3848(12)70003-8. Review.

PMID:
22221848
15.

Emergency department care for patients with hemophilia and von Willebrand disease.

Singleton T, Kruse-Jarres R, Leissinger C.

J Emerg Med. 2010 Aug;39(2):158-65. doi: 10.1016/j.jemermed.2007.12.024. Epub 2008 Aug 30. Review.

PMID:
18757163
16.

Inhibitor development in non-severe haemophilia across Europe.

Fischer K, Iorio A, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Gilman EA, Hollingsworth R, Makris M; EUHASS Participants.

Thromb Haemost. 2015 Oct;114(4):670-5. doi: 10.1160/TH14-12-1044. Epub 2015 Aug 13. Erratum in: Thromb Haemost. 2016 Mar;115(3):684. Hollingsworth, R [Added].

PMID:
26293381
17.

Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review.

Franchini M, Lippi G.

Thromb Haemost. 2010 Nov;104(5):931-40. doi: 10.1160/TH10-03-0151. Epub 2010 Sep 13. Review.

PMID:
20838738
18.

[Revision consensus hemophilia: treatment and responsibility. Nederlandse Vereniging van Hemophilia Patients].

Briët E, Mauser-Bunschoten EP.

Ned Tijdschr Geneeskd. 1997 Dec 27;141(52):2566-71. Review. Dutch.

PMID:
9555158
19.

The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.

Auerswald G, Spranger T, Brackmann HH.

Haematologica. 2003 Jun;88(6):EREP05. Review.

PMID:
12826531
20.

Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.

Brinkhous KM.

Wien Klin Wochenschr. 1982 Oct 15;94(19):509-14.

PMID:
6818773

Supplemental Content

Support Center